Brookfield Asset Management Has Trimmed Enbridge (ENB) Position By $15.14 Million; TIGENIX SA HEVERLEE ORDINARY SHARES BEL (TGXSF) SI Increased By 14.85%

April 25, 2018 - By Linda Rogers

TiGenix NV (OTCMKTS:TGXSF) Logo

TIGENIX SA HEVERLEE ORDINARY SHARES BEL (OTCMKTS:TGXSF) had an increase of 14.85% in short interest. TGXSF’s SI was 23,200 shares in April as released by FINRA. Its up 14.85% from 20,200 shares previously. The SI to TIGENIX SA HEVERLEE ORDINARY SHARES BEL’s float is 0.04%. The stock decreased 1.41% or $0.03 during the last trading session, reaching $2.1. About 5,000 shares traded or Infinity% up from the average. TiGenix NV (OTCMKTS:TGXSF) has 0.00% since April 25, 2017 and is . It has underperformed by 11.55% the S&P500.

Brookfield Asset Management Inc decreased Enbridge Inc (ENB) stake by 5.82% reported in 2017Q4 SEC filing. Brookfield Asset Management Inc sold 388,170 shares as Enbridge Inc (ENB)’s stock declined 21.20%. The Brookfield Asset Management Inc holds 6.28M shares with $246.33 million value, down from 6.67M last quarter. Enbridge Inc now has $50.16B valuation. The stock decreased 0.41% or $0.12 during the last trading session, reaching $29.27. About 5.65 million shares traded or 49.99% up from the average. Enbridge Inc. (NYSE:ENB) has declined 26.13% since April 25, 2017 and is downtrending. It has underperformed by 37.68% the S&P500.

TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. The company has market cap of $632.69 million. The Company’s stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. It currently has negative earnings. The companyÂ’s lead product candidate is the Cx601, which completed Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from CrohnÂ’s disease.

Among 16 analysts covering Enbridge Inc. (NYSE:ENB), 6 have Buy rating, 0 Sell and 10 Hold. Therefore 38% are positive. Enbridge Inc. had 25 analyst reports since August 4, 2015 according to SRatingsIntel. The stock has “Outperform” rating by BMO Capital Markets on Friday, October 23. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, March 23. The firm has “Market Perform” rating by Wolfe Research given on Monday, May 15. The stock has “Neutral” rating by Goldman Sachs on Wednesday, July 20. Morgan Stanley maintained Enbridge Inc. (NYSE:ENB) rating on Friday, February 9. Morgan Stanley has “Equal-Weight” rating and $38 target. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, October 9 report. The rating was maintained by Wells Fargo with “Market Perform” on Monday, April 3. The firm has “Equal-Weight” rating given on Friday, November 17 by Morgan Stanley. Credit Suisse maintained Enbridge Inc. (NYSE:ENB) on Tuesday, March 8 with “Neutral” rating. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, July 14.

Analysts await Enbridge Inc. (NYSE:ENB) to report earnings on May, 10. They expect $0.48 earnings per share, up 11.63% or $0.05 from last year’s $0.43 per share. ENB’s profit will be $822.58M for 15.24 P/E if the $0.48 EPS becomes a reality. After $0.48 actual earnings per share reported by Enbridge Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Brookfield Asset Management Inc increased American Homes 4 Rent (NYSE:AMH) stake by 395,700 shares to 8.06M valued at $175.94M in 2017Q4. It also upped American Tower Corp New (NYSE:AMT) stake by 430,500 shares and now owns 2.81 million shares. Simon Ppty Group Inc New (NYSE:SPG) was raised too.

Enbridge Inc. (NYSE:ENB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>